Gilead anticipates submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the fixed-dose combination following validation of the TMC278 NDA.
The word validation is needlessly obfuscating, IMO. GILD is saying that it will submit the NDA for the TMC278+Truvada combo pill when the FDA accepts JNJ’s TMC278 NDA for review, which should be about two months after JNJ submits the TMC278 NDA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.